CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

MethylPREDNISolone 80 Mg/mL Injectable SuspensionWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug2610 Use of social media during COVID-19 Wiki 1.00

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D003863 Depression, NIH 0.15
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm

This is a Phase II pilot exploratory study designed to investigate if prophylactic treatment with short term steroids administered to high risk Covid-19 patient might prevent cytokine storm and progression to respiratory failure. High risk is defined based on serologic markers of inflammation that include abnormalities of Interleukin 6 (IL-6), Ferritin , D-dimer, Lactate Dehydrogenase (LDH), as well as lymphopenia and impaired O2 saturation prior to or on the 7th day of first symptom of Covid-19.

NCT04355247 Covid-19 Drug: MethylPREDNISolone 80 Mg/mL Injectable Suspension

Primary Outcomes

Description: Clinical complete response criteria requires all the following: No need for ventilatory support at any point O2 Saturation of >/= 93% by day 14 of therapy Alive by day 28 from registration CT chest with minimal or no evidence of disease by day 28 from registration

Measure: Clinical complete response criteria

Time: 14 days

Description: Clinical Partial Response criteria require that 2 of the following be present by day 14 of therapy: No need for ventilatory support at any point O2 saturation > 93% bay day 14 from registration CT chest stable to improve over baseline by day 28 from registration

Measure: Clinical Partial Response criteria

Time: 14 days

Secondary Outcomes

Description: Decrease of at least 25% in anyone of the following markers: IL-6, Ferritin, D-dimer, C reactive protein (CRP) or LDH by day 14 - Improvement of absolute lymphocyte count in those presenting with lymphopenia. Improvement is defined as increase by 25% or more by day 14.

Measure: Secondary response criteria

Time: 14 days

No related HPO nodes (Using clinical trials)